Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Chicago Bayer |
---|---|
Information provided by: | University of Chicago |
ClinicalTrials.gov Identifier: | NCT00452218 |
The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
Condition | Intervention | Phase |
---|---|---|
Pulmonary Arterial Hypertension |
Drug: Sorafenib |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) |
Estimated Enrollment: | 12 |
Study Start Date: | March 2007 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Open: Experimental |
Drug: Sorafenib
200 mg daily and dose escalated to a maximum of 400 mg twice daily
|
Pulmonary arterial hypertension (PAH) is an angioproliferative vasculopathy resulting from abnormal endothelial and smooth muscle cell interactions. Idiopathic and familial PAH (formerly known as primary pulmonary hypertension) occurs more often in women than in men, with a median survival of 2.8 years if untreated and a mean age at diagnosis of 35 years. The key features of this vasculopathy causes a progressive narrowing of the pulmonary artery and their branches, resulting in right heart failure and death. Proliferating endothelial cells obliterate medium-sized precapillary arteries, thereby forming the characteristic "plexiform" lesions.
When combined with the expansion of both vascular smooth muscle cells and adventitial cells in pulmonary arteries, these observations evoke comparisons to cancer pathobiology. Currently, FDA-approved therapies for PAH such as prostacyclins (epoprostenol, treprostinil, and iloprost), endothelin receptor blockers (bosentan) and phosphodiesterase inhibitors (sildenafil) all produce functional improvement (6 minute walk distance- 6MW) with minimal change in hemodynamic measurements at cardiac catheterization. Only epoprostenol has provided survival benefit with the 5-year survival, remaining at 50% without demonstrable reversal of the vasculopathy. Clearly there is a critical need for novel targets and therapies for PAH.
In this protocol, the principal investigator (PI) will leverage a large PAH referral practice with an established clinical database to assess the potential utility of kinase inhibitors as a new class of agents for protease-activated receptor (PAR). These drugs inhibit processes important to pathological blood vessel branching and growth and have been a focus for the internationally renowned University of Chicago Phase I/II trials unit in oncology led by Dr. Mark Ratain (Co-Investigator). The University of Chicago has had a major role in the drug development of the recently (12/05) FDA-approved drug, sorafenib, for advanced renal carcinoma. Sorafenib inhibits Raf-1 kinase, a regulator of endothelial apoptosis, and inhibits angiogenesis growth factor receptors VEGFR-2, PDGFR-B, and VEGFR-3.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion Criteria
Cockcroft-Gault formula:
Female: creatinine clearance (ml/min)= 0.85 (140-age) x (body weight in kg)/ (72x serum creatinine in mg/dl)
United States, Illinois | |
The University of Chicago | |
Chicago, Illinois, United States, 60637 |
Principal Investigator: | Mardi Gomberg, M.D. | University of Chicago |
Responsible Party: | University of Chicago ( Mardi Gomberg-Maitland ) |
Study ID Numbers: | 14636A |
Study First Received: | March 26, 2007 |
Last Updated: | April 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00452218 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Pulmonary Arterial Hypertension PAH |
Respiratory Tract Diseases Hypertension, Pulmonary Lung Diseases Idiopathic Pulmonary Hypertension |
Vascular Diseases Protein Kinase Inhibitors Sorafenib Hypertension |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Vascular Diseases Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions Respiratory Tract Diseases |
Hypertension, Pulmonary Lung Diseases Therapeutic Uses Cardiovascular Diseases Sorafenib Hypertension |